Why the study?
Does long-term low-intensity warfarin therapy prevent recurrent VTE and reduce bleeding compared to conventional-intensity warfarin or placebo in patients with unprovoked VTE?
Does long-term low-intensity warfarin therapy prevent recurrent VTE and reduce bleeding compared to conventional-intensity warfarin or placebo in patients with unprovoked VTE?
Low-intensity warfarin is less effective than conventional-intensity warfarin but superior to placebo for preventing recurrent VTE, with a favorable bleeding profile.
Answers are grounded in this paper and cite their sources.
Low-intensity warfarin reduces major bleeding versus conventional-intensity but increases recurrent VTE risk; challenges lifelong conventional use and leaves optimal intensity open for unprovoked VTE.
BACKGROUND: Although there exists potential risk of bleeding, extended 'lifelong' conventional-intensity [international normalized ratio (INR): 2.0-3.0] warfarin anticoagulation is recommended for unprovoked venous thromboembolism (VTE) patients because of risk of recurrent VTE. Whether long-term low-intensity (INR: 1.5-2.0) warfarin therapy reduced the risk of major bleeding without substantially lowered antithrombotic efficacy is not well understood. The aim of this study was to perform a systematic review and meta-analysis to evaluate the risk-benefits of low-intensity warfarin therapy. METHODS: We conducted a comprehensive search of electronic databases and included randomized control trials (RCTs) that reported efficacy (recurrent VTE) and safety (bleeding episodes) of low-intensity warfarin therapy compared with conventional-intensity warfarin or placebo from inception through Jun 2016. RESULTS: Four RCTs reporting high GRADE quality evidence were included. Although the relative risk of recurrent VTE with low-intensity therapy was significantly increased [2.96 (95% CI: 1.40 to 6.24), P < .004] compared to conventional-intensity warfarin, there was significant decrease of relative risk when compared with placebo [0.37 (95% CI: 0.24 to 0.56), P < .00001]. As per included publications, no significant major bleeding episodes were observed in low-intensity warfarin group. CONCLUSIONS: Although less effective than conventional-intensity warfarin therapy this meta-analysis indicates that long-term low-intensity warfarin therapy is highly effective for preventing recurrent VTE than placebo, along with reduced risks of major bleeding and minimizing potential complications.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: